Breaking News

J&J Releases COVID-Vax Booster Data

Interim data from these studies demonstrate that a booster dose of the vaccine generated a rapid and robust increase in spike-binding antibodies.

Johnson & Johnson released data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with its single-shot vaccine.
 
In anticipation of the potential need for boosters, the J&J conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose.
 
The Company is engaging with the U.S. FDA, U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters